Reminder for uniQure Shareholders on Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy QURE?
Source: PRnewswire
- Class Action Notification: Rosen Law Firm reminds investors who purchased ordinary shares of uniQure N.V. (NASDAQ:QURE) between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval status and delays in its Biologics License Application for its Huntington's disease drug candidate, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource capabilities in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 15.600
Low
33.00
Averages
49.88
High
70.00
Current: 15.600
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder for uniQure Shareholders on Class Action Lawsuit
- Class Action Notification: Rosen Law Firm reminds investors who purchased ordinary shares of uniQure N.V. (NASDAQ:QURE) between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval status and delays in its Biologics License Application for its Huntington's disease drug candidate, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource capabilities in handling such cases.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action Lawsuit
- FDA Criticism: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a “failed therapy” during a media call, accusing the company of conducting a “distorted or manipulated comparison” in clinical studies, which could undermine investor confidence in the company's future prospects.
- Surgical Requirement Controversy: The FDA official dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that the agency did not request “drilling holes” but rather “one to three nicks in the scalp” under minimal anesthesia, potentially straining the company's relationship with the FDA.
- Legal Action Developments: The securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, with this omission likely leading to significant investor losses as the stock price plummeted.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, and failure to act promptly may result in losing the opportunity to represent their interests in the lawsuit, further intensifying scrutiny on the company's governance and transparency.
See More
uniQure Faces Securities Class Action Update Amid FDA Criticism
- Deadline Reminder: Hagens Berman law firm reminds investors that the Lead Plaintiff deadline for the securities class action against uniQure N.V. is April 13, 2026, and investors must apply by this date to represent others in the lawsuit.
- FDA Criticism Raises Concerns: On March 5 and 6, 2026, FDA officials labeled uniQure's gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of making 'distorted or manipulated comparisons' in its interactions with the FDA, which could negatively impact the company's reputation and stock price.
- Overview of Allegations: The securities class action, Scocco v. uniQure N.V., alleges that throughout the Class Period from September 24 to October 31, 2025, uniQure failed to disclose critical interactions with the FDA, potentially leading investors to make decisions without fully understanding the risks, thereby affecting the company's market performance.
- Whistleblower Incentives: Hagens Berman encourages insiders to utilize the SEC Whistleblower program, where providing original information can yield rewards of up to 30% of any successful recovery, which may attract more insiders to participate in the investigation, potentially impacting uniQure's future.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: ClaimsFiler reminds uniQure investors that lead plaintiff applications must be filed by April 13, 2026, for shares purchased between September 24 and October 31, 2025, highlighting investor concerns over potential legal risks associated with the company.
- Disclosure Failures: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors regarding the likelihood of FDA accelerated approval for their drug candidate AMT-130.
- Stock Price Plunge: Following the November 3, 2025 disclosure regarding FDA's stance on AMT-130, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, reflecting extreme market pessimism about the company's future prospects.
- Legal Implications: The case is pending in the Southern District of New York, and investors can seek legal assistance through ClaimsFiler, indicating a strong desire among investors to recover losses and raise questions about the company's governance.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action Lawsuit
- FDA Rebuke: An FDA official publicly labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of conducting a 'distorted or manipulated comparison' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Surgery Requirement Controversy: The FDA dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that it did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially impacting the design and execution of the company's clinical trials.
- Legal Action Update: The securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, a lack of disclosure that may have led to significant investor losses when the stock price fell.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, or risk losing the opportunity to seek compensation in the lawsuit, heightening the urgency for affected shareholders to act promptly.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. (NASDAQ: QURE) is facing a class action lawsuit for securities fraud, alleging significant misstatements and omissions regarding its Huntington's disease gene therapy drug during the class period from September 24 to October 31, 2025, potentially leading to substantial investor losses.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the FDA no longer accepted the data from uniQure's AMT-130 drug for BLA submission, the stock price plummeted by $33.40, or over 49%, from a closing price of $67.69 on October 31 to $34.29, severely impacting investor confidence.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP by April 13, 2026, to seek lead plaintiff status in the class action, highlighting investor concerns regarding corporate governance and transparency.
- Law Firm Background: Kessler Topaz Meltzer & Check, LLP is a leading law firm specializing in securities fraud class actions, having recovered over $25 billion for clients and represented major institutional investors, showcasing its significant influence and expertise in the securities litigation field.
See More
Reminder for uniQure Shareholders on Class Action Lawsuit
- Class Action Notification: Rosen Law Firm reminds investors who purchased ordinary shares of uniQure N.V. (NASDAQ:QURE) between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval status and delays in its Biologics License Application for its Huntington's disease drug candidate, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource capabilities in handling such cases.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action Lawsuit
- FDA Criticism: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a “failed therapy” during a media call, accusing the company of conducting a “distorted or manipulated comparison” in clinical studies, which could undermine investor confidence in the company's future prospects.
- Surgical Requirement Controversy: The FDA official dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that the agency did not request “drilling holes” but rather “one to three nicks in the scalp” under minimal anesthesia, potentially straining the company's relationship with the FDA.
- Legal Action Developments: The securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, with this omission likely leading to significant investor losses as the stock price plummeted.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, and failure to act promptly may result in losing the opportunity to represent their interests in the lawsuit, further intensifying scrutiny on the company's governance and transparency.
See More
uniQure Faces Securities Class Action Update Amid FDA Criticism
- Deadline Reminder: Hagens Berman law firm reminds investors that the Lead Plaintiff deadline for the securities class action against uniQure N.V. is April 13, 2026, and investors must apply by this date to represent others in the lawsuit.
- FDA Criticism Raises Concerns: On March 5 and 6, 2026, FDA officials labeled uniQure's gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of making 'distorted or manipulated comparisons' in its interactions with the FDA, which could negatively impact the company's reputation and stock price.
- Overview of Allegations: The securities class action, Scocco v. uniQure N.V., alleges that throughout the Class Period from September 24 to October 31, 2025, uniQure failed to disclose critical interactions with the FDA, potentially leading investors to make decisions without fully understanding the risks, thereby affecting the company's market performance.
- Whistleblower Incentives: Hagens Berman encourages insiders to utilize the SEC Whistleblower program, where providing original information can yield rewards of up to 30% of any successful recovery, which may attract more insiders to participate in the investigation, potentially impacting uniQure's future.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: ClaimsFiler reminds uniQure investors that lead plaintiff applications must be filed by April 13, 2026, for shares purchased between September 24 and October 31, 2025, highlighting investor concerns over potential legal risks associated with the company.
- Disclosure Failures: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors regarding the likelihood of FDA accelerated approval for their drug candidate AMT-130.
- Stock Price Plunge: Following the November 3, 2025 disclosure regarding FDA's stance on AMT-130, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 on October 31 to $34.29, reflecting extreme market pessimism about the company's future prospects.
- Legal Implications: The case is pending in the Southern District of New York, and investors can seek legal assistance through ClaimsFiler, indicating a strong desire among investors to recover losses and raise questions about the company's governance.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action Lawsuit
- FDA Rebuke: An FDA official publicly labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of conducting a 'distorted or manipulated comparison' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Surgery Requirement Controversy: The FDA dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that it did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially impacting the design and execution of the company's clinical trials.
- Legal Action Update: The securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, a lack of disclosure that may have led to significant investor losses when the stock price fell.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, or risk losing the opportunity to seek compensation in the lawsuit, heightening the urgency for affected shareholders to act promptly.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. (NASDAQ: QURE) is facing a class action lawsuit for securities fraud, alleging significant misstatements and omissions regarding its Huntington's disease gene therapy drug during the class period from September 24 to October 31, 2025, potentially leading to substantial investor losses.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the FDA no longer accepted the data from uniQure's AMT-130 drug for BLA submission, the stock price plummeted by $33.40, or over 49%, from a closing price of $67.69 on October 31 to $34.29, severely impacting investor confidence.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP by April 13, 2026, to seek lead plaintiff status in the class action, highlighting investor concerns regarding corporate governance and transparency.
- Law Firm Background: Kessler Topaz Meltzer & Check, LLP is a leading law firm specializing in securities fraud class actions, having recovered over $25 billion for clients and represented major institutional investors, showcasing its significant influence and expertise in the securities litigation field.
See More
